Abstract
IgG4 related sclerosing cholangitis (IgG4-SC) is a chronic cholestatic autoimmune
liver disease, characterized by obstruction of the biliary tract due to IgG4-positive
plasma cell infiltrations associated with fibrosis, phlebitis and presence of eosinophils.
The diagnosis of the disease is supported by elevation in serum IgG4, radiological
imaging and histology. In most of the cases IgG4-SC is associated with a wide spectrum
of symptoms and manifestations summarized by the definition of IgG4-related disease
(IgG4-RD). When the IgG4-SC causes an interruption of the biliary tract, differential
diagnosis with cholangiocarcinoma may become challenging, due to the anatomical difficulty
to get an appropriate histological pattern of the disease. Here we are describing
a case of a male patient admitted to our hospital for jaundice. The stenosis of biliary
ducts shown by radiologic imaging suggested Cholangiocarcinoma but, in the patient,
IgG4-SC was definitely diagnosed.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical diagnostic criteria of IgG4-related sclerosing cholangitis.J Hepatobiliary Pancreat Sci. 2012 Sep; 19: 536-542
- Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature.Hepatology. 2007; 45: 1547-1554
- Diagnosing Biliary Malignancy.Gastrointest Endosc Clin North America. 2015 Oct; 25: 677-690
- Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: a Systematic Review and Meta-analysis.In Vivo (Brooklyn). Mar-Apr 2020; 34: 479-488
- Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.Cancer Treat Res Commun. 2021; 27100337
- IgG4-related disease.Annu Rev Pathol. 2014; 9: 315-347
- Membranous nephropathy with repeated flares in IgG4-related disease.Clin Kidney J. 2013 February; 6: 204-207
- Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis.Clin Gastroenterol Hepatology. 2017 Jun; 15 (e3): 920-926
- Review of primary sclerosing cholangitis with increased IgG4 levels.World J Gastroenterol. 2020 June 21; 26: 3126-3144
- Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease.BMC Musculoskelet Disord. 2015 May 28; 16: 129
- The Utility of CA 19-9 in the Diagnosis of Cholangiocarcinoma in Patients Without Primary Sclerosing Cholangitis.World J Gastroenterol. 2004 Feb 1; 10: 427-432
- Differential diagnosis of immunoglobulin G4-associated cholangitis from cholangiocarcinoma.J Clin Gastroenterology. 2016 Jul; 50: 501-505
- Clinical practice guidelines for IgG4-related sclerosing cholangitis.J Hepatobiliary Pancreat Sci. 2019; 26: 9-42
- IgG4-Related Sclerosing Cholangitis.Curr Hepatol Rep. 2020; 19: 139-146
- Autoimmune diseases of the biliary tract: a review.Surg Clin North Am. 2019 Apr; 99 (Epub 2019 Feb 10): 185-201https://doi.org/10.1016/j.suc.2018.11.003
- Clinical features, response to treatment, and outcomes of IgG4-related Sclerosing Cholangitis.Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2016.12.038
- Management of primary sclerosing cholangitis and its complications: an algorithmic approach.Hepatol Int. 2021 Feb; 15: 6-20
- Current understanding of primary biliary cholangitis.Clin Mol Hepatol. 2021; 27: 1-21
- Primary sclerosing cholangitis.Lancet. 2018 Jun 23; 391: 2547-2559
- Atlas of Liver Pathology.Springer, 2013
- Liver MRI Correlation with Other Imaging Modalities and Histopathology.2nd Ed. Springer, 2014
Article info
Publication history
Published online: April 21, 2022
Accepted:
April 8,
2022
Received:
May 5,
2021
Identification
Copyright
© 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
